Daily Respiratory Research Analysis
Three impactful respiratory studies span vaccine design, lung injury mechanisms, and critical care management. A Cell study maps conserved betacoronavirus T cell epitope regions that enable broad cross-reactivity, guiding multi-antigen vaccine strategies. Mechanistic work links a STING–Drp1–N-GSDMD mitochondrial pathway to sepsis-induced lung injury, while a multicenter VV-ECMO cohort shows thrombocytopenia strongly predicts bleeding and reduced 6-month survival.
Summary
Three impactful respiratory studies span vaccine design, lung injury mechanisms, and critical care management. A Cell study maps conserved betacoronavirus T cell epitope regions that enable broad cross-reactivity, guiding multi-antigen vaccine strategies. Mechanistic work links a STING–Drp1–N-GSDMD mitochondrial pathway to sepsis-induced lung injury, while a multicenter VV-ECMO cohort shows thrombocytopenia strongly predicts bleeding and reduced 6-month survival.
Research Themes
- Pan-betacoronavirus T cell vaccine design using conserved epitope regions
- STING–mitochondria–pyroptosis axis in sepsis-induced lung injury
- Platelet kinetics and bleeding risk during VV-ECMO
Selected Articles
1. Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.
By mapping conserved T cell epitope regions across betacoronaviruses, the authors show robust cross-recognition by human T cells, especially when including non-spike antigens. These conserved regions cover 12% of the SARS-CoV-2 proteome and substantially increase HLA coverage and cross-reactivity versus spike-only targets.
Impact: Defines conserved, cross-reactive T cell targets across betacoronaviruses, providing a blueprint for pan-family, multi-antigen vaccines that may better withstand viral evolution.
Clinical Implications: Vaccine developers should prioritize inclusion of conserved non-spike T cell epitopes to broaden population HLA coverage and cross-protection, complementing neutralizing antibody strategies.
Key Findings
- Conserved T cell epitope regions (CTERs) comprise ~12% of the SARS-CoV-2 proteome.
- CTER-specific T cells cross-recognize sequences across multiple Betacoronavirus subgenera.
- Including non-spike CTERs markedly increases cross-reactivity and HLA coverage versus spike-only designs.
Methodological Strengths
- Integrated comprehensive epitope mapping with conservation analyses across viral subgenera
- Functional demonstration of human T cell cross-reactivity and HLA coverage impacts
Limitations
- No clinical efficacy data; translational impact inferred from immunological assays
- Potential HLA and population biases require validation in diverse cohorts
Future Directions: Evaluate multi-antigen vaccine constructs incorporating CTERs in preclinical models and early-phase trials; assess durability and breadth against divergent betacoronaviruses.
The COVID-19 pandemic highlighted the critical need for vaccine strategies capable of addressing emerging viral threats. Betacoronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS), and SARS-CoV-2, present significant pandemic risks due to their zoonotic potential and genetic diversity. T cell-mediated immunity has demonstrated durable responses and strong cross-reactivity, offering a promising avenue for achieving broad immunity within a viral family. In this study, we combined comprehensive epitope mapping with sequence conservation analyses to identify conserved T cell epitope regions (CTERs), which constitute 12% of the complete SARS-CoV-2 proteome. We showed that SARS-CoV-2 CTER-specific T cells cross-reactively recognize sequences from multiple Betacoronavirus subgenera. Importantly, incorporating CTERs from non-spike proteins significantly enhanced T cell cross-reactivity potential and human leukocyte antigen (HLA) coverage compared with T cells targeting only spike proteins. Our findings lay the groundwork for a multi-antigen vaccine strategy that includes non-spike proteins to expand cross-reactive immunity across a broader spectrum of Betacoronaviruses.
2. Inhibition of STING-induced mitochondrial Drp1/N-GSDMD-mediated MtDNA release alleviates Sepsis-induced lung injury.
The study delineates a macrophage STING–N-GSDMD–mtDNA positive feedback loop that drives pyroptosis and inflammation in ALI/ARDS models. STING regulates mitochondrial Ca2+, enabling Drp1–N-GSDMD interaction on mitochondria; disulfiram blocks mitochondrial N-GSDMD and mitigates injury.
Impact: Reveals a targetable mitochondria-centered mechanism linking STING activation to pyroptotic lung injury, identifying disulfiram-sensitive steps and connecting mitochondrial fission to inflammatory cell death.
Clinical Implications: Pharmacologic modulation of STING signaling and mitochondrial GSDMD/Drp1 interactions (e.g., with disulfiram or STING inhibitors) may offer new strategies for sepsis-induced ALI/ARDS, pending translational validation.
Key Findings
- Identifies a STING–N-GSDMD–mtDNA positive feedback loop in macrophages driving pyroptosis and inflammation in ALI/ARDS models.
- STING controls mitochondrial Ca2+ to promote Drp1–N-GSDMD interaction on mitochondria, linking fission to inflammatory cell death.
- GSDMD inhibitor disulfiram disrupts mitochondrial N-GSDMD anchoring and alleviates lung injury.
Methodological Strengths
- Convergent evidence across clinical ARDS (COVID-19) samples and LPS-ALI animal/cellular models
- Genetic and pharmacologic perturbations delineating Drp1–N-GSDMD–STING interactions
Limitations
- Translational gap: efficacy and safety of targeting this axis in humans remain untested
- LPS-induced ALI model may not capture full heterogeneity of sepsis-induced ARDS
Future Directions: Test STING pathway modulators and GSDMD/Drp1 inhibitors in translational ALI/ARDS models and early clinical trials; develop biomarkers of mitochondrial pyroptosis.
The stimulator of interferon genes (STING) pathway serves as a crucial nexus in inflammatory responses and cell death. Despite its role in Mitochondria-Endoplasmic Reticulum Contact (MERC), the mechanistic contributions to inflammatory outcomes remain poorly understood. In clinical acute respiratory distress syndrome (ARDS) models of COVID-19 infection and animal models of LPS-induced acute lung injury (ALI), the STING pathway is closely associated with the pyroptosis pathway. The macrophage STING-N-GSDMD-mtDNA positive feedback loop, upon LPS challenge, induces inflammatory responses and pyroptosis. The GSDMD inhibitor disulfiram (DSF) specifically abrogates the N-terminal portion of GSDMD anchored to the mitochondrial membrane. Furthermore, macrophage STING mediates the direct interaction between Drp1 and N-GSDMD on mitochondrial membrane by regulating mitochondrial calcium, linking mitochondrial fission to the induction of inflammatory responses. Targeting STING-mediated mitochondrial homeostasis, both genetically and pharmacologically, may play a protective role in preventing and treating sepsis-induced acute lung injury. Overall, our study posits that STING deficiency mitigates the cooperative interaction between N-GSDMD and Drp1 in mediating mitochondrial permeabilization and rupture following LPS challenge, paving the way for further investigations into inflammation and pyroptosis.
3. Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study.
In 652 adults on VV-ECMO, thrombocytopenia occurred in 80% at least once and was independently associated with increased bleeding and lower 6-month survival, especially below 100×10^9/L. These data quantify platelet kinetics and risk, informing transfusion and bleeding prevention strategies.
Impact: Provides multicenter, prospective evidence that platelet counts strongly correlate with bleeding and survival on VV-ECMO, supporting risk-adapted monitoring and transfusion thresholds.
Clinical Implications: Implement frequent platelet monitoring and consider proactive strategies (e.g., antithrombotic adjustments, transfusion thresholds) when counts approach <100×10^9/L to mitigate bleeding and improve outcomes.
Key Findings
- Baseline thrombocytopenia was present in 27.9% and developed at least once during ECMO in 80.2% of patients.
- Severity distribution during ECMO: mild 21.3%, moderate 32.2%, severe 26.7%.
- Lower platelet counts, particularly <100×10^9/L, were associated with higher bleeding risk and reduced 6-month survival.
Methodological Strengths
- Large multicenter, prospective observational design (n=652)
- Clinically relevant outcomes including bleeding and 6-month survival
Limitations
- Observational design limits causal inference; residual confounding possible
- Details on transfusion strategies and antithrombotic management not fully captured in abstract
Future Directions: Define evidence-based platelet transfusion thresholds and antithrombotic strategies in VV-ECMO via pragmatic trials; evaluate bleeding risk prediction tools incorporating platelet kinetics.
BACKGROUND: Thrombocytopenia is a recognized risk factor for bleeding during extracorporeal membrane oxygenation (ECMO). This study determines the incidence, risk factors, and clinical relevance of thrombocytopenia and platelet transfusions during venovenous (VV) ECMO. METHODS: The multicenter, prospective observational PROTECMO study included 652 adult patients who received VV ECMO for respiratory failure. Thrombocytopenia was classified as mild (100-149·10 RESULTS: A total of 182 patients (27.9%) had thrombocytopenia at baseline (mild in 14.7%, moderate in 8.7%, and severe in 4.4%). Thrombocytopenia during ECMO, at least once in 80.2% of patients, was mild in 21.3% of cases, moderate in 32.2%, and severe in 26.7%. A 10·10 CONCLUSIONS: Thrombocytopenia is highly prevalent in VV ECMO, and associated with a significant increase in the risk of bleeding, and a reduction in 6-month survival, particularly at platelet counts below 100·10